Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Diluted EPS of $5.90 per share (loss) for fiscal year 2025.
Corbus Pharmaceuticals Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$5.90 | -60.3% |
| 2024 | -$3.68 | +64.3% |
| 2023 | -$10.31 | -1.6% |
| 2022 | -$10.15 | +9.0% |
| 2021 | -$11.15 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.90 | -65.2% | -31.9% |
| June 30, 2025 | -$1.44 | -60.0% | -3.6% |
| March 31, 2025 | -$1.39 | -67.5% | -20.9% |
| September 30, 2024 | -$1.15 | +49.3% | -27.8% |
| June 30, 2024 | -$0.90 | +56.1% | -8.4% |
| March 31, 2024 | -$0.83 | +80.4% | +63.4% |
| September 30, 2023 | -$2.27 | -7.6% | -10.7% |
| June 30, 2023 | -$2.05 | +35.5% | +51.7% |
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -60.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Corbus Pharmaceuticals Holdings, Inc.’s diluted eps has grown by 47.1% (from $11.15 per share (loss) to $5.90 per share (loss)).
- The most recent figure is from Corbus Pharmaceuticals Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: